We Probed AI Search for Wound-Care Biologics Queries. Here's Who Gets Cited.
952 automated probes in July 2026 across wound-care biologics keywords. The target brand appeared in 12.9% of AI answers. Real competitor citation counts and what it means for clinical suppliers.
AI assistants have become a primary research channel for clinical decision-makers. When a wound care director or value analysis committee asks about biologics, amniotic matrices, or advanced wound care protocols, the answer they see is often generated by an LLM rather than a traditional search results page.
We wanted to know exactly who shows up in those answers. Between July 1 and July 12, 2026, we ran 952 automated probes across 56 keywords in the wound-care biologics category. The probes hit four different retrieval and answer systems: chatgpt-openclaw, serper, tavily, and standard web. Every probe recorded whether the target brand appeared in the answer, its rank if cited, and which competitor domains the engines surfaced instead.
Methodology
This was part of ongoing weekly GEO monitoring. We maintain a set of 50-plus buying and clinical queries that matter for a US supplier of amniotic and biologic wound matrices. Each day the system fires the full set against the four engines, parses the returned answers for citations, and logs every domain mentioned along with its position.
A "probe" is one keyword + one engine combination. Total: 952. The target brand (the specific biologics supplier we tracked) was marked "cited" only when the engine explicitly referenced it or its primary domain in the generated response. We also captured the full list of competitors_cited for every probe.
Keywords covered core terms such as "advanced wound care", "amniotic membrane diabetic foot ulcer", "wound care biologics 2026", "non-opioid wound care biologics", "amnioamp clinical outcomes", "wound biologics comparison", "antimicrobial matrix vs biologic allograft", and similar clinical and procurement phrases. Sample queries reflect real buyer language we see in the vertical.
Key Findings
The target brand was cited in 123 of the 952 probes.
12.9% citation rate.
That is low for a supplier trying to own the category. In the majority of answers, AI engines preferred other sources entirely.
Here are the top 10 most-cited domains across all probes (count = number of times the domain appeared in competitors_cited lists):
| Domain | Citations |
|---|---|
| pmc.ncbi.nlm.nih.gov | 254 |
| pubmed.ncbi.nlm.nih.gov | 111 |
| biotissue.com | 98 |
| www.sciencedirect.com | 80 |
| www.hmpgloballearningnetwork.com | 77 |
| woundreference.com | 72 |
| www.cms.gov | 54 |
| www.carlwilliamsplasticsurgery.com | 46 |
| rampartdl.com | 44 |
| www.facebook.com | 43 |
Academic and reference sources dominate. NCBI/PMC and PubMed together account for more than 365 appearances. Among commercial players, biotissue.com leads with 98, followed by woundreference.com (72) and rampartdl.com (44). Government (cms.gov) and journal sites also surface frequently.
Example Queries Where Patterns Appeared
The 56 keywords were not generic. Examples that triggered real differences in citation behavior included:
- amniotic membrane diabetic foot ulcer
- wound care biologics 2026
- non-opioid wound care biologics
- amnioamp clinical outcomes
- wound biologics comparison
- antimicrobial matrix vs biologic allograft
- advanced wound care products
- opioid-sparing wound management protocol
- dehydrated vs cryopreserved amniotic membrane
On many of these, the target brand was absent while the engines defaulted to the domains listed above or generic review content.
What the Numbers Mean for Clinical Suppliers
AI assistants are the new front door. A procurement director or clinician researching wound biologics is increasingly likely to ask ChatGPT, Perplexity, or an enterprise AI tool rather than open ten browser tabs. If your brand does not appear in the synthesized answer, you are not in the consideration set for that query.
The 12.9% citation rate is honest data from a real category scan. It is not zero, which means the brand has some presence, but it is far from owning the queries that should belong to it. The heavy presence of PubMed/PMC and review sites shows that engines currently favor established literature and reference platforms over direct manufacturer pages in this vertical.
This is not just an SEO problem anymore. It is a visibility problem in the layer where buying research now happens. Suppliers who treat GEO (generative engine optimization) as optional will watch share shift to whoever consistently appears in the answers, whether that is a direct competitor or an aggregator site.
Sample Size and Limitations
952 probes is a solid but not exhaustive sample. It covers 12 days and 56 keywords focused on one vertical. Results can shift with engine updates, new content publication, or changes in how the retrieval layers rank sources. We report the exact counts because small honest data is more useful than large fabricated claims.
Closing the Gap
The practical response is systematic: identify the exact queries where you are missing while competitors or reference sites are cited, produce targeted, evidence-backed content that answers those questions at the depth engines reward, and measure citation lift weekly the same way we probe.
That is the core of the work we do when suppliers engage us for GEO programs. The dashboard shows the before-and-after citation numbers in the same format as these probes.
If you supply clinical products and want to see your own market's current state, start with the free scanner. It runs the same style of probes against your category and returns who the engines actually cite today.
Run the free AI citation scan →
For suppliers ready for full strategy, execution, and ongoing measurement, the Growth program is built exactly for this: content that earns citations, tracked in real time.
You built it. We optimize it.